ClinicalTrials.gg
RecruitingNCT06042998CLASS14Updated Sep 21, 2023

A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer

An interventional study of Robotic radical gastrectomy in Gastric Cancer Stage II and Gastric Cancer Stage III, sponsored by The Affiliated Hospital of Qingdao University. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-09-21.

Sponsored by The Affiliated Hospital of Qingdao University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
588
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University — 12 open to participants now, 14 under way, 1 of them phase 3. Stomach Neoplasms · The Affiliated Hospital of Qingdao University.

Planned enrollment
2nd of 13
588 · median 300
Started
2023
with 3 others
No phase
12 of 16
9 open now
Primary completion
2024-12
later than 4 of 13 live
Registered
5th of 16
by date

Among the 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University, this one is the 2nd largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2023, is one of 12 with no phase, reaches primary completion later than 4 of the 13 other live ones, and was the 5th registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

12 of the 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Stomach Neoplasms by The Affiliated Hospital of Qingdao University, or all of them as a file.
02

Study summary

To evaluate the clinical efficacy of robot radical Gastrectomy and laparoscopic radical Gastrectomy, patients with gastric adenocarcinoma (cT2N+M0 or cT3-4a/N+M0, phase II and III) undergoing neoadjuvant treatment were selected as subjects.

Read the detailed description
  1. Research background In the world, gastric cancer is a common malignant tumor, with the incidence rate ranking fourth and tumor related deaths ranking second. Although the incidence rate of gastric cancer in western countries has a downward trend, it still remains at a high level in East Asia. China is a high incidence area of gastric cancer and a traditional country of gastric cancer. A large number of cases have brought patients a heavy Disease burden.

    Unlike early diagnosis and treatment in developed countries such as Japan and South Korea, gastric cancer in China is mostly diagnosed in the middle to late stage, and the treatment effect is not yet satisfactory. Locally advanced gastric cancer remains the main challenge for the treatment of gastric cancer. The current treatment strategy for locally advanced gastric cancer is a multidisciplinary treatment strategy centered on surgery. Since the MAGIC trial, neoadjuvant chemotherapy for gastric cancer has been widely accepted. Possible advantages of neoadjuvant therapy include better patient tolerance, tumor progression, and elimination of occult micro metastasis to improve radical resection and better prognosis.

    Since the first laparoscopic gastric cancer surgery reported by Kitano et al. in 1994, it has undergone more than 20 years of continuous exploration and innovation. Laparoscopic gastric cancer surgery has rapidly developed worldwide and has now been widely recognized both domestically and internationally. A large number of studies on laparoscopic gastric cancer surgery and laparotomy have confirmed that Laparoscopy has the advantages of less complications, less blood loss during operation, less postoperative pain and inflammatory reaction, rapid recovery of gastrointestinal function, short postoperative hospital stay, and good cosmetic effect, and the oncological treatment effect is equivalent to that of open surgery. At present, laparoscopic surgery for gastric cancer is gradually developing, but the traditional Laparoscopy is limited in fine operation, vision and other aspects. In order to overcome the limitations of laparoscopic surgery, the da Vinci robot system has emerged. As an advanced laparoscopic system, the robot has solved many shortcomings of conventional laparoscopy with its unique advantages. A clearer field of view can better display small anatomical structures, which is conducive to achieving skeletonization of gastric perivascular structures. At the same time, it reduces the difficulty of lymph node dissection and bleeding. At the same time, it has a simulated wrist with 7 degrees of freedom, greatly improving the flexibility of operation and reducing the difficulty of suturing. In the field of gastric cancer surgery, since Hashizume et al. first reported robot gastric cancer surgery in 2002, there have been increasing reports on the safety and feasibility of robot surgical systems applied to gastric cancer treatment. At present, a large number of studies have confirmed that compared with Laparoscopy, robotic surgery can also achieve radical resection, and has the advantages of less intraoperative blood loss and more lymph nodes to be cleared.

    However, the safety and effectiveness of da Vinci surgery are still unclear for patients after neoadjuvant chemotherapy. The pro fibrotic response caused by chemotherapy and the loss of normal tissue planes caused by cytotoxicity pose new technological challenges. Whether less trauma and more lymph node dissection are equivalent to better postoperative safety, chemotherapy completion rate, and survival benefits remains a key issue in clinical practice. Previous RCT studies have shown that LADG seems to provide better postoperative safety and adjuvant chemotherapy tolerance than ODG for locally advanced gastric cancer patients receiving neoadjuvant chemotherapy. Therefore, further targeted research is needed to explore robotic gastric cancer surgery for neoadjuvant therapy.

    Based on the above background, the safety and effectiveness of robotic Gastrectomy in gastric cancer patients undergoing new adjuvant treatment is a key clinical problem in gastric surgery that needs to be solved urgently. Therefore, on the basis of traditional laparoscopy and robotic laparoscopy, this study compared the short-term and long-term clinical efficacy of Leonardo da Vinci Gastrectomy in the neoadjuvant treatment of gastric cancer with gastric adenocarcinoma patients undergoing neoadjuvant treatment.

  2. Research Purpose To evaluate the clinical efficacy of robot radical Gastrectomy and laparoscopic radical Gastrectomy, patients with gastric cancer (cT2N+M0 or cT3-4a/N+M0, phase II and III) undergoing neoadjuvant treatment were selected as subjects.
  3. Research Design Adopting a multicenter, prospective, open, randomized, controlled, and non-inferiority validation design.

3.2 Comparison and grouping Group A (experimental group): Performing robot radical gastrectomy for gastric cancer Group B (control group): Performing laparoscopic radical gastrectomy for gastric cancer 3.3 Estimation of Sample Size This study used the 3-year disease-free survival rate (DFS) as the main efficacy evaluation indicator. Using 1:1 random grouping, The planned collection of cases is 1.5 years, and the last case will be followed up for another 3 years after enrollment. Due to the lack of previous similar research results, the dual standard method described in Neuenschwander et al.'s paper was used to calculate the required sample size to determine the non disadvantages of robotic versus laparoscopic gastric cancer radical surgery based on DFS [20]. The first criterion is the critical threshold for HR valuation to be less than 1.08, while the second criterion requires that the upper limit of the one-sided 95% confidence interval for non inferiority margin valuation be less than 1.24. The inspection level is taken as 0.05 (bilateral), and the inspection efficiency is taken as 0.8. Using PASS calculation, the sample size N=269, which means that each group requires 268 people. Considering possible exclusion and loss of follow-up cases (10% dropout rate), the final sample size required for each group is 294, with a total of 588 cases required.

3.4 Blind method: This study adopts an open design 3.5 Research cycle Case enrollment cycle: Complete the required case enrollment within 1.5 years. Follow up period: The first case is included as the starting point for follow-up, and the main research purpose is 3 years after the last case is included End point of follow-up. Expected time: June 2023- December 2024 (completion of enrollment) - December 2027 (completion of follow-up) 3.6 Randomization This study adopts a central dynamic randomization method based on minimization, considering stratified factors such as age, BMI, preoperative staging, chemotherapy regimen, and tumor location. After each case is selected, a dedicated person from the participating research center is responsible for inputting the selected case information (age, BMI, preoperative staging, neoadjuvant treatment plan, tumor location) into the central randomization system. The system will immediately return the randomization results to the research center. Researchers from each participating research center should strictly follow the grouping to determine whether the subjects will enter Group A (experimental group) or Group B (control group).

03

Conditions studied

  • Gastric Cancer Stage II
  • Gastric Cancer Stage III

Browse trials for

Keywords

  • Neoadjuvant therapy
  • gastric cancer
  • robot radical gastrectomy
  • laparoscopic Gastrectomy
  • short-term clinical outcome
  • prognosis
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years old ≤ 75 years old male or female;
  2. The primary gastric lesion was diagnosed as gastric adenocarcinoma (papillary adenocarcinoma, tubular adenocarcinoma, mucinous adenocarcinoma, Signet ring cell carcinoma, poorly differentiated adenocarcinoma) by endoscopic histopathology;
  3. Before treatment, the preoperative clinical staging was confirmed to be II and III (cT2N+M0 or cT3-4a/N+M0) through gastroscopy/ultrasound gastroscopy, enhanced CT/MR, or diagnostic laparoscopic exploration (based on AJCC-8th TNM tumor staging);
  4. 2-4 cycles of neoadjuvant therapy (chemotherapy+/- targeted/immunotherapy, simple chemotherapy);
  5. After new adjuvant treatment, radical Gastrectomy is feasible after MDT discussion;
  6. Preoperative physical condition score of 0/1 or Karst score ≥ 70%;
  7. Preoperative I-III;
  8. The expected survival period exceeds 6 months;
  9. Willing and able to comply with the research protocol;
  10. Sign a written form before enrollment and be fully aware of the right to withdraw from this study at any time.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating women;
  2. Suffering from serious mental illness;
  3. History of upper abdominal surgery (excluding history of laparoscopic cholecystectomy);
  4. History of gastric surgery (excluding ESD/EMR for gastric cancer);
  5. Moderate to severe renal insufficiency;
  6. Organ transplant recipients receiving therapy;
  7. Have a history of other malignant diseases within 5 years;
  8. Have a history of unstable angina or myocardial infarction within 6 months;
  9. Have a history of cerebral infarction or cerebral hemorrhage within 6 months;
  10. Have a history of continuous systemic therapy within one month;
  11. Simultaneous surgical treatment of other diseases is required (excluding laparoscopic cholecystectomy);
  12. Gastric cancer comorbidities (bleeding, perforation, obstruction) requiring emergency surgery;
  13. Lung function test \<50% of expected value;
  14. The patient has participated or is currently participating in other clinical studies (within 6 months).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
588 participants (estimated)

Study arms

  • Experimental
    Robotic group

    Robotic gastrectomy

    Procedure: Robotic radical gastrectomy

  • Active comparator
    Laparoscopic group

    Laparoscopic gastrectomy

    Procedure: Robotic radical gastrectomy

Interventions

  • ProcedureRobotic radical gastrectomy

    Laparoscopic gastrectomy

    Also known as: Laparoscopic gastrectomy

06

What researchers measure

Primary outcomes

  1. 3-year disease-free survival

    3-year disease-free survival

    Time frame: three years after surgery

Secondary outcomes

  1. 3-year overall survival rate

    3-year overall survival rate

    Time frame: three years after surgery

  2. overall postoperative morbidity rates

    overall postoperative morbidity rates

    Time frame: 30 days after surgery

  3. postoperative recovery course

    postoperative recovery course

    Time frame: 14 days surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Sharing data with participating centers

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Dec 2024, 17 months after the start.

Of 358 non-industry interventional studies with no phase under Stomach Neoplasms, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 63. This study's planned 17 months is below that.

Counting every sponsor, half of 369 studies reached it within 36 months; a quarter within 17 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2023
First posted
Sep 21, 2023
StartActual
Jul 7, 2023
Primary completionEst.
Dec 30, 2024
CompletionEst.
Dec 30, 2027
Last update
Sep 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06042998
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Jul 7, 2023
Primary completion
Dec 30, 2024 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Sep 21, 2023

Study contacts

Yanbing Zhou
Contact
zhouyanbing999@aliyun.com
13708971773

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion